The F38-Like Group,a New Group of Caprine Mycoplasmas?

This paper concerns the taxonomic status of the F38-like group (MacOwan), a prime determinant of contagious caprine pleuropneumonia (CCPP). Extensive biochemical and serological investigations on strain F38 are reported. Some complex serological relationships with other mycoplasma species are revealed. The results, taken in conjunction with earlier published work on geno-typic characters, lead to the conclusion that final classification of these organisms should await further comparative studies of a number of field strains with a related group of strains classified as M. capri-colum.The characterization of F38 confirms its partial relationship to the “M. mycoides group” of ovine/caprine/bovine mycoplasmas, and has also revealed a very close phenotypic relationship to the bovine mycoplasma serogroup 7, a finding of potential diagnostic and epidemiological importance.Key words: mycoplasmas, classification, F38-like group     

Sarcocystis spp. infections in naturally infected cats and dogs: levels of sporocyst production and the influence of host, environmental and seasonal factors on the prevalence of infection

Data obtained from faecal samples from 508 domestic cats and 481 dogs, previously found to have a high frequency of Sarcocystis spp. infections, were further examined to provide information on levels of sporocyst shedding and to ascertain the influence of host, environmental and seasonal factors on the prevalence of naturally acquired infections. Statistical analysis of prevalence data revealed that, of the factors examined, only host age in cats exerted any apparent influence. Infections were significantly more common in cats up to, rather than over, 6 months of age. Although they tended to be greater in dogs than cats, faecal sporocyst counts in both hosts were generally low, with the majority of infected samples containing 200 sporocysts per gram or less. In infected dogs the highest count recorded was 144,600/g with a mean of 2270/g, and in infected cats it was 11,100/g with a mean of 597/g.     

Failure of orally administered zinc to prevent experimentally induced footrot in sheep

Two groups of adult Merino sheep, initially grazed on pasture, were dosed daily with zinc sulphate (1 mg Zn/kg LW) or zinc oxide (15 mg Zn/kg LW) for six and seven weeks, respectively. On the 18th day, both groups were transferred to indoor pens together with unmedicated control sheep, and five days later the feet of all animals were infected artificially with a virulent strain of Bacteroides nodosus. By the fourth week after challenge, 85% or more of the feet challenged had developed advanced footrot, and no significant differences in the incidence and severity of lesions between dosed and un-dosed groups were recorded. Plasma zinc concentrations, monitored throughout the experiment, remained at similar levels in sheep receiving the lower dose rate and in the controls. At the higher dose rate, plasma zinc levels increased till Day 23, but thereafter declined to values comparable to those of undosed animals. At post mortem, no evidence of zinc toxicosis was found, and only the kidneys of sheep receiving the higher dosage showed a significant accumulation of zinc compared with the controls.     

Oxfendazole resistance in Nematodirus spathiger

The occurrence of anthelmintic resistance in a field strain of Nematodirus spathiger is reported for the first time. In a controlled anthelmintic trial with naturally-acquired infections, oxfendazole at 5 mg/ kg and levamisole at 8 mg/kg were 0 and 86% effective respectively, against this strain.     

Colonic perforation after corticosteroid and surgical treatment of intervertebral disk disease in a dog

Colonic perforation after corticosteroid and surgical treatment of intervertebral disk disease in a dog Perforation of the distal segment of the descending colon, after corticosteroid and neurosurgical treatment for an intervertebral disk herniation, resulted in the death of a 3-year-old, male, Lhasa Apso. Initially, the dog was paraparetic in the hindlimbs, but became paraplegic after 4 days of conservative treatment. Corticosteroids were administered before referral and during decompressive hemilaminectomy. Six days after surgery, the dog had improved neurologically, but was depressed, anorectic, and vomiting. Abdominocentesis revealed septic peritonitis. The dog died shortly after a perforation in the descending colon was surgically corrected.     

Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure

The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.     

Biotechnology in the marine sciences

Genetic engineering applied to the production of fish, molluscs, algae, algal products, and crustaceans in natural environments and hatchery systems is still at the rudimentary stage. Cloning systems for producing commercially important chemicals, pharmacologically active compounds, and metamorphosis-stimulating substances present in marine organisms are being sought. Attempts are being made to develop useful drugs from the sea, including antineoplastic, antibiotic, growth-promoting (or -inhibiting), analgesic, and antispasmodic agents. Immediate commercial applications can be expected from engineered systems involving polysaccharide and specialty chemical production, with marine microorganisms as the source of genetic material.